Durham.

PositionTriangle

DURHAM--Drugmaker BioCryst Pharmaceuticals will purchase San Francisco-based Presidio Pharmaceuticals for $101 million. The combined company will target infectious diseases, such as hepatitis C and...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT